C. J. Poole

1.7k total citations
21 papers, 680 citations indexed

About

C. J. Poole is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. J. Poole has authored 21 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. J. Poole's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (5 papers). C. J. Poole is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (5 papers). C. J. Poole collaborates with scholars based in United Kingdom, Austria and South Sudan. C. J. Poole's co-authors include R W Russell, Helena Earl, Janet Dunn, Louise Hiller, S. Bowden, Carlos Caldas, H. Raza Ali, Fiona M. Blows, Elena Provenzano and Sarah‐Jane Dawson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

C. J. Poole

20 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. J. Poole United Kingdom	11	478	287	170	134	85	21	680
A. Reinacher-Schick Germany	11	441 0.9×	149 0.5×	146 0.9×	175 1.3×	61 0.7×	46	636
Su Hwan Kang South Korea	14	452 0.9×	358 1.2×	160 0.9×	226 1.7×	54 0.6×	59	842
Gilad W. Vainer Israel	14	257 0.5×	245 0.9×	213 1.3×	297 2.2×	78 0.9×	28	700
Nobue Kumaki Japan	14	300 0.6×	201 0.7×	144 0.8×	135 1.0×	86 1.0×	47	600
Marie‐Christine Baranzelli France	12	219 0.5×	169 0.6×	185 1.1×	145 1.1×	40 0.5×	32	531
Yoshimasa Kosaka Japan	17	381 0.8×	207 0.7×	162 1.0×	362 2.7×	105 1.2×	46	805
Pierre Bohanes United States	16	592 1.2×	205 0.7×	266 1.6×	350 2.6×	110 1.3×	52	1.0k
Pamela Tan Australia	5	341 0.7×	273 1.0×	86 0.5×	182 1.4×	83 1.0×	6	643
Tilmann Lantzsch Germany	14	294 0.6×	209 0.7×	101 0.6×	237 1.8×	119 1.4×	26	819
Kuniko Sunami Japan	16	320 0.7×	196 0.7×	297 1.7×	150 1.1×	42 0.5×	47	638

Countries citing papers authored by C. J. Poole

Since Specialization

Citations

This map shows the geographic impact of C. J. Poole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. J. Poole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. J. Poole more than expected).

Fields of papers citing papers by C. J. Poole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. J. Poole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. J. Poole. The network helps show where C. J. Poole may publish in the future.

Co-authorship network of co-authors of C. J. Poole

This figure shows the co-authorship network connecting the top 25 collaborators of C. J. Poole. A scholar is included among the top collaborators of C. J. Poole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. J. Poole. C. J. Poole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pivot, Xavier, C. J. Poole, Joseph Gligorov, et al.. (2018). The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program. European Journal of Cancer. 92. S105–S106. 1 indexed citations

Pivot, Xavier, C. J. Poole, Miguel Martín, et al.. (2016). An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies. Annals of Oncology. 27. vi63–vi63. 1 indexed citations

Dunn, Janet, JMS Bartlett, Peter Hall, et al.. (2016). OPTIMA: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. UCL Discovery (University College London). 3 indexed citations

Ali, H. Raza, Fiona M. Blows, Elena Provenzano, et al.. (2015). PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology. 26(7). 1488–1493. 228 indexed citations

Rea, Daniel, Richard Gray, S. Bowden, et al.. (2013). Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer. European Journal of Cancer. 49. 17 indexed citations

García, Agustin A., Ignace Vergote, John P. Micha, et al.. (2011). The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).. Journal of Clinical Oncology. 29(15_suppl). 5047–5047. 4 indexed citations

Leo, Angelo Di, Christine Desmedt, J. M. S. Bartlett, et al.. (2010). Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 519–519. 11 indexed citations

Leo, Angelo Di, J Isola, Fanny Piette, et al.. (2009). A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.. Cancer Research. 69(2_Supplement). 705–705. 42 indexed citations

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2008). tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). Journal of Clinical Oncology. 26(15_suppl). 506–506. 27 indexed citations

10.

Wardley, Andrew, Louise Hiller, Helen Howard, et al.. (2008). tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer. 99(4). 597–603. 14 indexed citations

11.

Gray, Richard, et al.. (2008). aTTom (adjuvant Tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results. Journal of Clinical Oncology. 26(15_suppl). 513–513. 48 indexed citations

12.

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2006). Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. Breast Cancer Research and Treatment. 100. 1 indexed citations

13.

Poole, C. J., M. Gore, P. Vasey, et al.. (2005). Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 23(16_suppl). 5017–5017. 2 indexed citations

14.

Poole, C. J., Helena Earl, Mark Verrill, et al.. (2001). Hypothesis P53 mutation as basis for effect of paclitaxel-containing therapy on ER-negative tumours and of tamoxifen in obfuscating this in ER-positive in CALGB9344. European Journal of Cancer. 37. 1–2.

15.

Poole, C. J., et al.. (2001). A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK. European Journal of Cancer. 37. 4–4. 2 indexed citations

16.

Nemunaitis, John, C. J. Poole, John Primrose, et al.. (1998). Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.. PubMed. 4(5). 1101–9. 174 indexed citations

17.

Kehoe, Sean, et al.. (1994). A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. British Journal of Cancer. 69(3). 537–540. 4 indexed citations

18.

Poole, C. J., R W Russell, Paul Harrison, & Geoffrey F. Savidge. (1987). Amaurosis fugax under the age of 40 years.. Journal of Neurology Neurosurgery & Psychiatry. 50(1). 81–84. 27 indexed citations

19.

Joseph, Rajiv, et al.. (1985). Thromboxane Synthetase Inhibition: Potential Therapy in Migraine. Headache The Journal of Head and Face Pain. 25(4). 204–207. 5 indexed citations

20.

Poole, C. J. & R W Russell. (1985). Mortality and stroke after amaurosis fugax.. Journal of Neurology Neurosurgery & Psychiatry. 48(9). 902–905. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact